In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy
Novo Nordisk blames middlemen in U.S. healthcare system for high prices of weight loss drugs Wegovy and Ozempic
Read Next
- Wall Street extends its record run. Weak PMI data pressures AUD :: InvestMacro
- FIS reengineers its Private Capital Suite
- Europe’s work-life balance could be key in Trump’s H-1B visa shake-up
- Lightspeed introduces Lightspeed Trader Pro
- Secret Service dismantles telecom threat around UN capable of crippling cell service in NYC
- Startup Zerohash raises $104M from Morgan Stanley, SoFi, Apollo
- Citi introduces Citi Stylus Workspaces with Agentic AI
